Toripalimab had manageable side effects in patients with refractory cholangiocarcinoma and exhibited preliminary evidence of anti-tumor activity. However, further information regarding biomarkers is needed. ClinicalTrials.gov ID: NCT03474640.
No takes yet. Share an insight, caveat, or question.
Naing et al. (2025) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: